Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions
Executive Summary
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
You may also be interested in...
Australian Body Welcomes Passage Of Shortages Law
Legislation setting out measures to mitigate shortages in Australia has been passed by the country’s senate, incorporating into law key provisions of new five-year pact between the off-patent industry and the government.
Australia's Competition Regulator Authorizes Another Year Of Close Collaboration
Australian off-patent industry association GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the Australian Competition and Consumer Commission has decided, extending an existing authorization by a further year.
Another Year Of Close Collaboration Authorized In Australia
Australian off-patent industry association the GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the ACCC has decided, extending an existing authorization by a further year.